Within3 has appointed Ira Daly as chief operating officer, placing the longtime biopharmaceutical business development executive in charge of the company’s commercial growth, client success, and strategic partnerships.
Daly joins Within3 after more than 18 years at IQVIA, where he built and led business development teams serving pharmaceutical, biotechnology, and medical technology companies across multiple therapeutic areas.
Most recently, Daly was senior vice president of offering development at IQVIA. He assembled a cross-functional team of data and analytics specialists and developed artificial intelligence agents intended to improve how the company delivers solutions and supports customers.
Daly previously served as senior vice president of biotechnology and midsize business development for the U.S. and Canada. He managed a large business development organization and established relationships with biotechnology companies, academic institutions, venture capital firms, and patient groups.
As Within3’s chief operating officer, Daly will align its business development, client success, and strategic partnership teams. His priorities include expanding relationships with emerging biotechnology companies and global pharmaceutical organizations and helping customers derive measurable value from Within3’s platform and services.
The company’s technology combines public and private information with expert networks to generate evidence for clinical and commercial decisions. Within3 says its platform is used by all 20 of the largest pharmaceutical companies.
Daly will focus on positioning Within3 as a long-term partner embedded with clients’ business and technology teams. His appointment also reflects the company’s effort to connect product intelligence with the strategic questions affecting treatments throughout their commercial lifecycles.
He holds a master’s degree in cell and molecular biology from Fordham University and a bachelor’s degree in chemistry from Saint Joseph’s University.
KEY QUOTES
“Ira understands that the most valuable partnerships in our industry are built over years, not contracts, and that is exactly what Within3 needs as we enter our next phase of growth.”
Erin Mistry, Chief Executive Officer of Within3
“Throughout my career, I’ve seen how the right partner can influence the success of a development program, if and how physicians prescribe the treatment, and ultimately its commercial success. Within3 offers biopharma teams something they’ve never had: a connected, real-time view of the market, so they can act when it matters most. I’m excited to help more clients put that intelligence to work and to build partnerships that deliver measurable results.”
Ira Daly, Chief Operating Officer of Within3

